New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin);  ;  ; leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) - injection with diluent - 22.5 mg - active: leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin);  ;  ; leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) - injection with diluent - 30 mg - active: leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin);  ;  ; leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) - injection with diluent - 45 mg - active: leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

Canada - English - Health Canada

tolmar international ltd. - leuprolide acetate - powder for suspension, sustained-release - 7.5mg - leuprolide acetate 7.5mg - antineoplastic agents

Canada - English - Health Canada

tolmar international ltd. - leuprolide acetate - powder for suspension, sustained-release - 22.5mg - leuprolide acetate 22.5mg - antineoplastic agents

Canada - English - Health Canada

tolmar international ltd. - leuprolide acetate - powder for suspension, sustained-release - 30mg - leuprolide acetate 30mg - antineoplastic agents

Canada - English - Health Canada

tolmar international ltd. - leuprolide acetate - powder for suspension, sustained-release - 45mg - leuprolide acetate 45mg - antineoplastic agents